<DOC>
	<DOCNO>NCT01616446</DOCNO>
	<brief_summary>The purpose study evaluate whether difference pharmacokinetics cyclosporine remission nephrotic syndrome compare relapsed disease child .</brief_summary>
	<brief_title>Pharmacokinetics Cyclosporin Nephrotic Syndrome</brief_title>
	<detailed_description>This prospective study ten child use Cyclosporin-A ( CSA ) microemulsion treat idiopathic nephrotic syndrome ( INS ) , normal renal function , achieve complete remission CSA . The objective compare pharmacokinetic ( PK ) parameter CSA INS remission relapse disease . The PK profile CSA evaluate 12-hour area time-concentration curve ( AUC0-12 ) use seven time-point sample . This procedure do patient remission relapse CSA dose mg/kg/day . The AUC0-12 calculate trapezoidal rule . All PK parameter resume 4-hour area time-concentration curve ( AUC0-4 ) correlate AUC0-12 . This study important cyclosporin nephrotoxic drug narrow therapeutic window .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>child steroidresistant nephrotic syndrome steroiddependent nephrotic syndrome use cyclosporine renal function evaluate creatinine clearance estimate stature â‰¥ 90 ml/min/1.73m2 cyclosporine trough level ( C0 ) 50 150 ng/ml complete remission cyclosporine accord guideline International Society Kidney Diseases Children renal hepatic function abnormality presence infectious disease clinical histological sign CSA nephrotoxicity suspicious noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>cyclosporin</keyword>
	<keyword>nephrotic syndrome</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>child</keyword>
</DOC>